DE69534165D1 - Adenovirus mit glutathion peroxydate gene - Google Patents

Adenovirus mit glutathion peroxydate gene

Info

Publication number
DE69534165D1
DE69534165D1 DE69534165T DE69534165T DE69534165D1 DE 69534165 D1 DE69534165 D1 DE 69534165D1 DE 69534165 T DE69534165 T DE 69534165T DE 69534165 T DE69534165 T DE 69534165T DE 69534165 D1 DE69534165 D1 DE 69534165D1
Authority
DE
Germany
Prior art keywords
adenovirus
peroxydate
glutathion
gene
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69534165T
Other languages
English (en)
Other versions
DE69534165T2 (de
Inventor
Martine Barkats
Jacques Mallet
Frederic Revah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of DE69534165D1 publication Critical patent/DE69534165D1/de
Application granted granted Critical
Publication of DE69534165T2 publication Critical patent/DE69534165T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01009—Glutathione peroxidase (1.11.1.9)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
DE69534165T 1994-08-12 1995-07-26 Adenovirus mit glutathion peroxydate gene Expired - Lifetime DE69534165T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9409982A FR2723588B1 (fr) 1994-08-12 1994-08-12 Adenovirus comprenant un gene codant pour la glutathion peroxydase
FR9409982 1994-08-12
PCT/FR1995/001002 WO1996005320A1 (fr) 1994-08-12 1995-07-26 Adenovirus comprenant un gene codant pour la glutathion peroxydase

Publications (2)

Publication Number Publication Date
DE69534165D1 true DE69534165D1 (de) 2005-05-25
DE69534165T2 DE69534165T2 (de) 2006-03-09

Family

ID=9466290

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69534165T Expired - Lifetime DE69534165T2 (de) 1994-08-12 1995-07-26 Adenovirus mit glutathion peroxydate gene

Country Status (14)

Country Link
US (2) US20010029249A1 (de)
EP (1) EP0775213B1 (de)
JP (1) JPH10504193A (de)
AT (1) ATE293700T1 (de)
AU (1) AU710727B2 (de)
CA (1) CA2197235C (de)
DE (1) DE69534165T2 (de)
FI (1) FI970579A (de)
FR (1) FR2723588B1 (de)
IL (1) IL114904A0 (de)
MX (1) MX9700851A (de)
NO (1) NO970282L (de)
WO (1) WO1996005320A1 (de)
ZA (1) ZA956678B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6814962B1 (en) * 1994-06-02 2004-11-09 Aventis Pharma S.A. Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6200799B1 (en) * 1997-06-03 2001-03-13 University Of Lausanne Somatic gene therapy to suppress secondary cataract formation following eye surgery
CA2308606A1 (en) 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
PT1047784E (pt) 1998-01-14 2009-12-21 Novartis Vaccines & Diagnostic Antigénios de neisseria meningitidis
EP2261346A3 (de) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Antigene und Zusammensetzungen gegen Neisseria meningitidis
EP2278007B1 (de) 1999-04-30 2014-04-16 Novartis Vaccines and Diagnostics S.r.l. Konservierte Antigene aus Neisseria
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
CA2954411A1 (en) 1999-10-29 2001-05-03 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigenic peptides
DK1897555T3 (da) 2000-01-17 2014-10-13 Novartis Vaccines & Diagnostic Kompletteret OMV-vaccine mod meningococcus
SG165981A1 (en) 2000-10-27 2010-11-29 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
NZ546711A (en) 2001-12-12 2008-06-30 Chiron Srl Immunisation against chlamydia trachomatis
CA2470583C (en) * 2001-12-18 2011-03-15 Xiangqun Gao Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
PT1736541E (pt) 2004-03-29 2013-01-31 Galpharma Co Ltd Nova proteína galectina 9 modificada e sua utilização
EP2054431B1 (de) 2006-06-09 2011-08-31 Novartis AG Bakterielle adhäsine konformere
US10947500B2 (en) * 2014-06-27 2021-03-16 Angiocrine Bioscience, Inc. Neural cells expressing adenovirus E4ORF1, and methods of making and using the same
CN110108883A (zh) * 2018-10-27 2019-08-09 广州呼吸健康研究院 用于筛选与靶治疗ards患者的msc精准医学的标志物组合

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007541A1 (en) * 1987-04-01 1988-10-06 Chiron Corporation Polynucleotide construct encoding a polypeptide substantially similar to human glutathione peroxidase
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
JPH0327289A (ja) 1989-06-22 1991-02-05 Toyo Jozo Co Ltd 新規な血漿型グルタチオン・パーオキシダーゼ遺伝子およびその用途
AU3969993A (en) * 1992-04-01 1993-11-08 Cornell Research Foundation Inc. Method and recombinant cells for providing increased resistance of hematopoietic progenitor cells to toxicity of chemotherapeutic agents
WO1994027612A1 (en) 1993-05-20 1994-12-08 Baylor College Of Medicine Genetic therapy for cardiovascular disease
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
US7252989B1 (en) * 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system

Also Published As

Publication number Publication date
US7241591B2 (en) 2007-07-10
US20040175363A1 (en) 2004-09-09
EP0775213B1 (de) 2005-04-20
CA2197235A1 (fr) 1996-02-22
WO1996005320A1 (fr) 1996-02-22
ATE293700T1 (de) 2005-05-15
FI970579A0 (fi) 1997-02-11
NO970282D0 (no) 1997-01-22
EP0775213A1 (de) 1997-05-28
AU710727B2 (en) 1999-09-30
MX9700851A (es) 1997-04-30
FR2723588A1 (fr) 1996-02-16
CA2197235C (fr) 2010-07-20
FR2723588B1 (fr) 1996-09-20
AU3082695A (en) 1996-03-07
IL114904A0 (en) 1995-12-08
FI970579A (fi) 1997-02-11
JPH10504193A (ja) 1998-04-28
US20010029249A1 (en) 2001-10-11
NO970282L (no) 1997-01-22
DE69534165T2 (de) 2006-03-09
ZA956678B (en) 1996-03-20

Similar Documents

Publication Publication Date Title
DE69534165D1 (de) Adenovirus mit glutathion peroxydate gene
BR9608449A (pt) Vìrus recombinante defeituoso, adenovìrus, uso de um vìrus, e, composição farmacêutica.
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
TR200200938T2 (tr) CCR5 modülatörleri olarak piperidinler
NO962791D0 (no) Preparater inneholdende nukleinsyrer, deres fremstilling og anvendelse
BR9405507A (pt) Adenovirus recombinante defeituoso linhagem celular e composição farmaceutica
HUP0300246A2 (en) Delivery system
ATE333464T1 (de) Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika
ATE280826T1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
MX9606327A (es) Adenovirus que comprende un gen que codifica para un superoxido dismutasa.
ATE204297T1 (de) Peptidanaloge des lh-rh, ihre verwendungen und die sie enthaltenden pharmazeutischen zusammensetzungen
DE69422169D1 (de) Modifizierte proteine und peptide enthaltende pharmazeutische mittel
ATE273031T1 (de) Aminobiguanide und ihre verwendung zur desinfektion von kontaktlinsen und konservierung von pharmazeutischen zubereitungen
ES2168457T3 (es) Composiciones farmaceuticas que comprenden una superoxido dismutasa.
BG103968A (en) Pharmaceutical antiviral composition containing glycirricinic acid and at least one protein with antiviral activity
FI940375A (fi) Peptidit, joilla on elimiä suojaavaa vaikutusta, menetelmä niiden valmistamiseksi ja niiden käyttö terapiassa
DE69520475D1 (de) Pharmaceutische Zusammensetzung von biologisch aktiven Peptiden oder Proteinen
IT1270618B (it) Proteine ad attivita' antitumorale
TR199901190T2 (xx) Interferon-(alfa) N�kleik asitlerinin verilmesi ve sentezlenmesi i�in y�ntemler ve bile�imler.
MX9700298A (es) Adenovirus que comprende un gen que codifica para una no sintasa.
BR9802803A (pt) ação e composições farmacêuticas contendo os mesmos.
DE69831737D1 (de) Neurotrypsin
PT983300E (pt) Sais peptidicos de bpc com actividade organo-protectora, processo para a sua preparacao e sua utilizacao em terapia
IT1294967B1 (it) Composizione immunogenica da tlp
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune

Legal Events

Date Code Title Description
8364 No opposition during term of opposition